...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Liquidity

BDAZ/Toinv

Based on RVX's 4/30/19 Financial Statements, Note 12, Royalty Preferred Shares,

I compute a value of Royalty Preferred Shares of ~ $800MM USD, or $10 per share.

This assumes RVX has a positive top-line and revenues commence 12/31/2022.

Since Zenith Capital owns these shares  they will have adequate funding 

for development of their portfolio.

 

If RVX does not have a positive top-line, ZEL will need funding  

jmo

Soon we will have the answers

Chicagoest

 

Share
New Message
Please login to post a reply